Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
September 11, 2025
Gosselies, Belgium
About us
Bioxodes
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with intracerebral hemorrhage (ICH). Bioxodes is also preparing a Phase 2 trial with BIOX-101 in ischemic stroke.
BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful antithrombotic effect. Crucially, it does so without increasing bleeding.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and NETs formation.
BIOX-101 is our lead asset, topping a pipeline of therapeutic candidates targeting thrombo-inflammatory diseases. We are currently preparing for a Phase 2b clinical trial of BIOX-101 in intracerebral hemorrhage (ICH), a condition with significant unmet medical need. BIOX-101 has received Orphan Drug Designation in both Europe and the U.S. for this indication.
video testimonial
Prof Robin Lemmens, a world-renowned stroke expert, is the lead Investigator of the current Phase 2a trial for BIOX-101.
“Stroke is worldwide one of the main causes for mortality,” he says in this video. “We are really in need to find medication hear to try and improve their prognosis.” Professor Lemmens, the head of the stroke unit at the University Hospital Leuven (Belgium), was speaking at an investor event Bioxodes had organized in Zurich, in February 2024.
Product
All products-
![]()
BIOX-101
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Read more -
![]()
Pipeline
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Read More -
![]()
Clinical trials
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
Read More
Advisory Board
All Key Opinion Leaders-
Read more
Robin Lemmens , M.D.
Leuven, Belgium
-
Read more
Rustam Al-Shahi Salman , MA MB BChir PhD FRCP Edin FHEA FESO
Edinburgh, United Kingdom
-
Read more
Matthias Endres , M.D.
Berlin, Germany
-
Read more
David Seiffge , M.D.
Bern, Switzerland
-
Read more
Charlotte Cordonnier , M.D.
Lille, France
-
Read more
Denis Vivien , Ph.D
Caen, France
-
Read more
Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)
Brussels, Belgium
-
Read more
Ashkan Shoamanesh , M.D.
Hamilton, Canada
-
Read more
Magdy Selim , M.D., PhD.
Boston, United-States
Recents News
Accurate Diagnosis And Enrollment Criteria Improve Intracerebral Hemorrhage Research
July 02, 2025
Intracerebral hemorrhage (ICH) is responsible for half of all stroke-related deaths but attracts only a fraction of the attention its better-known relative ischemic stroke gets. At Bioxodes, a clinical-phase biotech company, we faced a poignant consequence of this paradox when we struggled to recruit sufficient ICH patients into a clinical trial. Trial protocols are based largely on experiences with ischemic stroke patients, investigators noticed, which are very different from those with ICH. This real-life example underscores that not only is ICH a disease that needs better research funding, it also needs more public awareness.
How Bioxodes is rewriting the rules of haemorrhagic stroke treatment
July 01, 2025
Namur, Belgium
There is currently no approved treatment for intracerebral haemorrhage (ICH), the deadliest form of stroke. But Bioxodes, a Walloon start-up, believes the answer may lie in one of nature’s most unlikely places: the saliva of ticks. The company is developing a drug inspired by this natural compound and could become the first to commercialise a treatment for ICH, potentially changing the outlook for thousands of patients worldwide.
Bioxodes plans to raise EUR 70m to bring to market its hemorrhagic stroke drug candidate – CEO
June 30, 2025
Bioxodes plans to raise EUR 70m in a Series B round to finance the completion of clinical trial andbring to market its hemorrhagic stroke drug candidate, CEO Marc Dechamps said. The Belgian biotechnology company started talks with investors in April, following the receipt ofpositive interim data from the Phase 2a study, he said. It plans to complete the funding round by late2026 or 2027, targeting global VCs as investors, he added. Management has mandated KBC Securities to assist with the funding round, Dechamps said.
Investors
Invest in us
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
